<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-------------------------
FORM 8-K/A
AMENDMENT NO. 1
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported) MAY 7, 1997
ELECTROPHARMACOLOGY, INC.
- --------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
DELAWARE 0-25828 95-4315412
- ---------------- ---------------- ----------------
(State of (Commission (IRS Employer
Incorporation) File Number) Identification No.)
2301 N.W. 33RD COURT, SUITE 102 33069
------------------------------- -----------
POMPANO BEACH, FLORIDA
----------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (954) 975-9818
<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
AMENDMENT TO APPLICATION OR REPORT
FILED PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
ELECTROPHARMACOLOGY, INC.
FORM 8-K/A
AMENDMENT NO. 1
The undersigned registrant hereby amends Item 7 of its Form 8-K dated May 7,
1997 and previously filed with the Commission on May 7, 1997 in its entirety as
follows:
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits:
--------
Exhibit
Number Exhibit
------ -------
1 Strategic Alliance Agreement dated as of May 1, 1997
between Electropharmacology, Inc. and National Patient
Care Systems, Inc.*
- --------------------
* Confidential portions of this exhibit have been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24b-2
under the Securities Exchange Act of 1934, as amended.
-2-
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
ELECTROPHARMACOLOGY, INC.
By: /s/ Arup Sen
Dr. Arup Sen
President and Chief Executive Officer
Date: June 11, 1997
-3-
<PAGE>
EXHIBIT INDEX
-------------
The following exhibit is filed herewith:
Exhibit
Number Exhibit
------ -------
1 Strategic Alliance Agreement dated as of May 1, 1997
between Electropharmacology, Inc. and National Patient
Care Systems, Inc.*
- --------------------
* Confidential portions of this exhibit have been omitted and filed with
the Securities and Exchange Commission pursuant to Rule 24b-2 under the
Securities Exchange Act of 1934, as amended.
<PAGE>
Jones, Day, Reavis & Pogue
2300 Trammell Crow Center
2001 Ross Avenue
Dallas, Texas 75201
June 11, 1997
Via EDGARlink
- -------------
Securities and Exchange Commission
450 Fifth Street, N.W.
Washington, DC 20549
Re: Electropharmacology, Inc.
File No. 0-25828; Form 8-K filed May 7, 1997
--------------------------------------------
Gentlemen:
On behalf of Electropharmacology, Inc. ("Company"), enclosed for filing
is Amendment No. 1 to the Company's Form 8-K dated May 7, 1997 and previously
filed with the Securities and Exchange Commission ("Commission") on May 7, 1997
pursuant to Section 13 of the Securities Exchange Act of 1934, as amended.
A confidential treatment request for certain portions of the Form 8-K
("CTR") was filed with the Commission by the Company on May 7, 1997. Subsequent
to that date, the Company received a letter from the Staff of the Commission
dated May 21, 1997, advising that the exhibit index of the public copy of the
Form 8-K filed on May 7, 1997, should indicate that certain portions of the
exhibit have been omitted based upon the CTR. Amendment No. 1 therefore amends
the Form 8-K to indicate in the exhibit index that certain portions of the
exhibit have been omitted based upon a request for confidential treatment.
In addition, the name of one of the parties in the document forming the
exhibit had been inadvertently misstated. Accordingly, the reference to the
party in the exhibit index of the Form 8 K/A has been revised. The exhibit
itself has not been re-filed as the change is not deemed to be material.
Please contact either myself at (214) 969-3705 or Fiona Arnold at (214)
969-4845 if you have any questions or if we can be of any further assistance.
Very truly yours,
/s/ Richard K. Kneipper
cc: NASDAQ
